Upstream Bio, Inc. (UPB)
2.74
-0.25
(-8.36%)
USD |
NASDAQ |
Oct 23, 16:00
2.735
0.00 (0.00%)
After-Hours: 20:00
Upstream Bio Total Liabilities (Quarterly) : 10.21M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.21M |
| March 31, 2026 | 14.06M |
| December 31, 2025 | 14.00M |
| September 30, 2025 | 12.61M |
| Date | Value |
|---|---|
| June 30, 2025 | 11.78M |
| March 31, 2025 | 10.56M |
| December 31, 2024 | 11.87M |
| September 30, 2024 | 12.14M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Sutro Biopharma, Inc. | 297.78M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 281.17M |
| Shareholders Equity (Quarterly) | 270.96M |
| Debt to Equity Ratio | 0.0035 |
| Current Ratio | 27.99 |
| Net Debt Paydown Yield | 0.04% |